Cover Image
市場調查報告書

利什曼原蟲症(黑熱病):開發中產品分析

Leishmaniasis (Kala-Azar) - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 192676
出版日期 內容資訊 英文 97 Pages
訂單完成後即時交付
價格
Back to Top
利什曼原蟲症(黑熱病):開發中產品分析 Leishmaniasis (Kala-Azar) - Pipeline Review, H1 2017
出版日期: 2017年05月23日 內容資訊: 英文 97 Pages
簡介

所謂利什曼原蟲症,是人被雌的白蛉沙蠅叮咬時感染寄生蟲發病的感染疾病。主要的症狀,有體重減輕和血球數的減少,肝臟、脾臟的肥大化,發熱等。主要的治療藥有抗寄生蟲劑等。

本報告提供全球各國的利什曼原蟲症(黑熱病)治療用的開發中產品的開發情形相關分析,產品開發、上市的最新趨勢,及臨床實驗的各階段的產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊,為您概述為以下內容。

目錄

簡介

  • 分析範圍

利什曼原蟲症(黑熱病)概要

治療藥的開發

  • 利什曼原蟲症的開發中產品:概要
  • 各企業的開發平台
  • 各大學/研究機關的開發中產品
  • 企業開發中的產品
  • 大學/研究機關開發中的產品

治療藥的評估

  • 各標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

利什曼原蟲症開發治療藥的企業

  • Advinus Therapeutics Ltd
  • BioLingus AG
  • 第一三共
  • iCo Therapeutics Inc.
  • Laboratorios LETI SL
  • ManRos Therapeutics
  • Matinas BioPharma Holdings Inc
  • Nanomerics Ltd
  • Novartis AG
  • Oblita Therapeutics BVBA

藥物簡介

利什曼原蟲症治療藥:開發暫停的產品

利什曼原蟲症治療藥:開發中止的產品

利什曼原蟲症相關產品的開發里程碑

  • 值得注意的最新趨勢、新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9344IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Leishmaniasis (Kala-Azar) - Pipeline Review, H1 2017, provides an overview of the Leishmaniasis (Kala-Azar) (Infectious Disease) pipeline landscape.

Leishmaniasis is an infection caused by a parasite that is spread to people through the bite of the female phlebotomine sand fly. Symptoms include weight loss, low blood counts, enlargement of the liver and spleen and fever. Treatment includes anti-parasitic drugs.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Leishmaniasis (Kala-Azar) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Leishmaniasis (Kala-Azar) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Leishmaniasis (Kala-Azar) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Leishmaniasis (Kala-Azar) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical, Discovery and Unknown stages are 3, 11, 8 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 1, 10 and 9 molecules, respectively.

Leishmaniasis (Kala-Azar) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Leishmaniasis (Kala-Azar) (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Leishmaniasis (Kala-Azar) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Leishmaniasis (Kala-Azar) (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Leishmaniasis (Kala-Azar) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Leishmaniasis (Kala-Azar) (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Leishmaniasis (Kala-Azar) (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Leishmaniasis (Kala-Azar) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Leishmaniasis (Kala-Azar) - Overview
    • Leishmaniasis (Kala-Azar) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Leishmaniasis (Kala-Azar) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Leishmaniasis (Kala-Azar) - Companies Involved in Therapeutics Development
    • Advinus Therapeutics Ltd
    • BioLingus AG
    • Daiichi Sankyo Company Ltd
    • iCo Therapeutics Inc.
    • Laboratorios LETI SL
    • ManRos Therapeutics
    • Matinas BioPharma Holdings Inc
    • Nanomerics Ltd
    • Novartis AG
    • Oblita Therapeutics BVBA
  • Leishmaniasis (Kala-Azar) - Drug Profiles
    • (gentamicin sulfate + paromomycin sulfate) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • 18-MC - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • amphotericin B - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • amphotericin B - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • amphotericin B - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • amphotericin B - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Amphotericin B sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • candicidin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CDRI-99288 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • D-121 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drugs for Leishmaniasis and Trypanosomiasis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GNF-6702 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • hypoestoxide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • interferon gamma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KVH-14 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • leishmaniasis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • leishmaniasis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • leishmaniasis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • leishmaniasis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • leishmaniasis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NPC-1161B - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • P-MAPA - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Peptides for Infectious Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • S-015-2344 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Leishmaniasis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Leishmaniasis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Visceral Leishmaniasis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit SOD for Chagas Disease and Leishmaniasis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Infectious Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Infectious Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Leishmaniasis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Leishmaniasis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Leishmaniasis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Leishmaniasis and Chagas Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Visceral Leishmaniasis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Visceral Leishmaniasis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize CD206 for Leishmaniasis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit HDAC for Oncology and Infectious Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Lanosterol 14 alpha-Demethylase for Chagas Disease, Leishmaniasis and African Trypanosomiasis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Leishmania Major Casein Kinase 1 Isoform 2 for Leishmaniasis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit LHR1 for Leishmaniasis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Nucleoside Hydrolase for Leishmaniasis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides for Infectious Disease - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine for Leishmaniasis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • visceral leishmaniasis vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Leishmaniasis (Kala-Azar) - Dormant Projects
  • Leishmaniasis (Kala-Azar) - Discontinued Products
  • Leishmaniasis (Kala-Azar) - Product Development Milestones
    • Featured News & Press Releases
      • Nov 28, 2016: iCo Therapeutics Announces Positive Study Results and Significant Advances related to Oral Amphotericin B Program
      • Aug 08, 2016: A single compound could treat three parasitic diseases
      • Dec 15, 2015: U.S. Issues Patent on Corifungin
      • Oct 26, 2015: iCo Therapeutics Announces Manufacturing Update for Oral Amp B Program
      • Feb 13, 2015: Nanomerics Oral Amphotericin B Promises Better Treatment for Millions
      • Oct 06, 2014: Phase III Clinical Study in Ethiopia Launched to Test Two Treatments for HIV-Visceral Leishmaniasis Co-infected Patients
      • Feb 26, 2013: National Institutes of Health Supports Acea's Research
      • Mar 06, 2012: £10 million boost for neglected tropical disease research at Dundee
      • Feb 22, 2012: IDRI Launches First Clinical Trial For New Vaccine To Treat Leishmaniasis
      • Oct 24, 2011: iCo Therapeutics Oral Amphotericin B Delivery System To Be Presented At AAPS
      • Jul 01, 2011: FDA issues orphan-drug designation to Corifungin
      • Sep 29, 2010: iCo Therapeutics Oral Amphotericin Program Receives FDA Orphan Drug Status
      • Feb 10, 2010: Dr. Jose Vazquez presents poster at ICAAC
      • Dec 14, 2005: Collaboration on the Development of Anti-Parasitic Drugs for Both Malaria and Leishmaniasis
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Leishmaniasis (Kala-Azar), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Leishmaniasis (Kala-Azar) - Pipeline by Advinus Therapeutics Ltd, H1 2017
  • Leishmaniasis (Kala-Azar) - Pipeline by BioLingus AG, H1 2017
  • Leishmaniasis (Kala-Azar) - Pipeline by Daiichi Sankyo Company Ltd, H1 2017
  • Leishmaniasis (Kala-Azar) - Pipeline by iCo Therapeutics Inc., H1 2017
  • Leishmaniasis (Kala-Azar) - Pipeline by Laboratorios LETI SL, H1 2017
  • Leishmaniasis (Kala-Azar) - Pipeline by ManRos Therapeutics, H1 2017
  • Leishmaniasis (Kala-Azar) - Pipeline by Matinas BioPharma Holdings Inc, H1 2017
  • Leishmaniasis (Kala-Azar) - Pipeline by Nanomerics Ltd, H1 2017
  • Leishmaniasis (Kala-Azar) - Pipeline by Novartis AG, H1 2017
  • Leishmaniasis (Kala-Azar) - Pipeline by Oblita Therapeutics BVBA, H1 2017
  • Leishmaniasis (Kala-Azar) - Dormant Projects, H1 2017
  • Leishmaniasis (Kala-Azar) - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Leishmaniasis (Kala-Azar) - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Leishmaniasis (Kala-Azar), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top